Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 06.05.2021.

#NBTInTheirWords
#ALS
#innovation
#startup
#healthcare
#webinar

Healthcare

@emilylmullin shared
On May 3, 2021
Six dementia patients went to Mexico last year to get an unapproved gene therapy meant to stop their telomeres from shortening. Is it research or medical tourism? https://t.co/gb58z6Aowy
Open
Six patients with dementia went to Mexico for an unproven gene therapy, a biotech CEO claims

Six patients with dementia went to Mexico for an unproven gene therapy, a biotech CEO claims

The study is part of an effort by entrepreneurs and scientists, dreamers and schemers, to demonstrate aging is not inevitable.

@NatureBiotech shared
On Apr 30, 2021
When the FDA asked for a second trial for Amylyx's #ALS drug, even though it met its primary endpoint in a phase 2/3 trial, patient advocates and caregivers responded with dismay #NBTInTheirWords via @statnews https://t.co/zNSWfClyqf https://t.co/fwrUPcmcwA
Open
ALS groups to the FDA and drug sponsors: ‘We won’t be played again’

ALS groups to the FDA and drug sponsors: ‘We won’t be played again’

The FDA and pharma companies politely nod when listening to ALS patients, caregivers, and advocates, but don't take action.

@Biotechnology shared
On May 5, 2021
Money on the Move: April 29 – May 4 https://t.co/YS33dPOXlt https://t.co/YMM9T7BvHu
Open
Money on the Move: April 29 – May 4

Money on the Move: April 29 – May 4

April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world.

@CDRLifeSciences shared
On May 5, 2021
RT @EnteromeSA: We are thrilled to announce that Catherine Mathis, our Chief Development Officer, is participating in the BioLabs Biotech Startup Series: The path to IND on May 27 at 4 pm CET. 📚 Free event, register here: https://t.co/XRiBuPVFTW #startup #healthcare #innovation #webinar https://t.co/qwfzI3RBjq
Open
Biotech Startup Series: The Path to IND

Biotech Startup Series: The Path to IND

The Path to IND The Biotech Start-up Series of conferences and webinars focuses on healthcare entrepreneurship, gathering American & European entrepreneurs, researchers and experts to ...

@Biotechnology shared
On May 5, 2021
Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene https://t.co/QQBqZIZtDK https://t.co/g8O4REIyH5
Open
Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene

Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene

There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.

@CDRLifeSciences shared
On May 4, 2021
Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund https://t.co/Rifq9thnmm https://t.co/lYonQ4XluD
Open
Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund

Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund

/PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led by the Dementia Discovery...

@Biotechnology shared
On Apr 30, 2021
COVID Innovations: Vaccines for Variants, Drone Deliveries, Print-Your-Own Shots, and More https://t.co/rpDox1yYgO https://t.co/3envVpkWjs
Open
COVID Innovations: Vaccines for Variants, Drone Deliveries, Print-Your-Own Shots, and More

COVID Innovations: Vaccines for Variants, Drone Deliveries, Print-Your-Own Shots, and More

Next-generation COVID-19 vaccines will not only tackle different versions of the virus but will provide solutions across the world at a fraction of the cost

@Dominic_Tyer shared
On May 3, 2021
Episode 35: Galapagos UK’s Michael Smyth on RNA-based technology and market access https://t.co/wGXw29gV1B
Open
Episode 35: Galapagos UK’s Michael Smyth on RNA-based technology and market access

Episode 35: Galapagos UK’s Michael Smyth on RNA-based technology and market access

The new episode of the pharmaphorum podcast also hears about some of pharma’s UK launch challenges and the types of evidence that HTA bodies need for RNA-based drugs